Furthermore, to demonstrate that CCl2 expression is dependent on EGFR signaling, Erlotinib was used as EGFR signaling pathway inhibitor which significantly reduced CCL2 expression in GBM cells, as shown by western blot and ELISA assays. This evidence concerns the gene CCL2 and glioblastoma.